Login Register Cart 0
General Review Article

循环生物标志物用于直肠癌对新辅助放化疗的反应预测

卷 27, 期 25, 2020

页: [4274 - 4294] 页: 21

弟呕挨: 10.2174/0929867326666190507084839

价格: $65

摘要

直肠癌对新辅助放化疗的反应高度可变。实际上，据估计仅约21％的患者在治疗后表现出病理完全缓解（pCR），而在大多数患者中，观察到部分或不完全的肿瘤消退。因此，具有先天性放化疗耐药性肿瘤的患者不应接受治疗，这与严重的不良反应相关，并且不能保证任何临床益处。对于局部晚期直肠癌患者（LARC），使用标准化的新辅助治疗方案，对预后或预测性生物标志物的识别和有用性可以改善抗肿瘤治疗策略，改变放疗，化学疗法和手术切除的顺序，剂量以及组合。由于这些原因，越来越多的研究实际上集中在发现和研究对pCRT反应的新的预测性生物标志物上。在本综述中，我们选择了有关使用可能预测LARC患者中pCR的基于血液的生物标志物的最新文献（2012-2017），我们进行了严格的讨论以强调其实际临床益处以及所提出方法的当前局限性方法。

关键词: 直肠癌，新辅助药物，预测性生物标志物，基于血液的生物标志物，放射疗法，化学疗法。

« Previous
[1]
DeSantis, C.E.; Lin, C.C.; Mariotto, A.B.; Siegel, R.L.; Stein, K.D.; Kramer, J.L.; Alteri, R.; Robbins, A.S.; Jemal, A. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin., 2014, 64(4), 252-271.
[http://dx.doi.org/10.3322/caac.21235] [PMID: 24890451]
[2]
Siegel, R.L.; Miller, K.D.; Fedewa, S.A.; Ahnen, D.J.; Meester, R.G.S.; Barzi, A.; Jemal, A. Colorectal cancer statistics, 2017. CA Cancer J. Clin., 2017, 67(3), 177-193.
[http://dx.doi.org/10.3322/caac.21395] [PMID: 28248415]
[3]
Tamas, K.; Walenkamp, A.M.; de Vries, E.G.; van Vugt, M.A.; Beets-Tan, R.G.; van Etten, B.; de Groot, D.J.; Hospers, G.A. Rectal and colon cancer: Not just a different anatomic site. Cancer Treat. Rev., 2015, 41(8), 671-679.
[http://dx.doi.org/10.1016/j.ctrv.2015.06.007] [PMID: 26145760]
[4]
Massarweh, N.N.; Artinyan, A.; Chang, G.J. Neoadjuvant treatment for rectal cancer-A value-based proposition. J. Surg. Oncol., 2016, 114(3), 304-310.
[http://dx.doi.org/10.1002/jso.24267] [PMID: 27111410]
[5]
Sauer, R.; Becker, H.; Hohenberger, W.; Rödel, C.; Wittekind, C.; Fietkau, R.; Martus, P.; Tschmelitsch, J.; Hager, E.; Hess, C.F.; Karstens, J.H.; Liersch, T.; Schmidberger, H.; Raab, R. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med., 2004, 351(17), 1731-1740.
[http://dx.doi.org/10.1056/NEJMoa040694] [PMID: 15496622]
[6]
Bosset, J.F.; Collette, L.; Calais, G.; Mineur, L.; Maingon, P.; Radosevic-Jelic, L.; Daban, A.; Bardet, E.; Beny, A.; Ollier, J.C. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med., 2006, 355(11), 1114-1123.
[http://dx.doi.org/10.1056/NEJMoa060829] [PMID: 16971718]
[7]
Greene, F.L. American Joint Committee on Cancer., and American Cancer Society., AJCC cancer staging manual; 6th ed; Springer-Verlag. xiv: New York,. , 2002.
[8]
Edge, S. Edge, S.B and American Joint Committee on Cancer., AJCC cancer stag-ing manual,; 7th ed; Springer. xiv: New York. , 2010.
[9]
Brown, C.L.; Ternent, C.A.; Thorson, A.G.; Christensen, M.A.; Blatchford, G.J.; Shashidharan, M.; Haynatzki, G.R. Response to preoperative chemoradiation in stage II and III rectal cancer. Dis. Colon Rectum, 2003, 46(9), 1189-1193.
[http://dx.doi.org/10.1007/s10350-004-6714-y] [PMID: 12972962]
[10]
de Campos-Lobato, L.F.; Stocchi, L.; da Luz Moreira, A.; Geisler, D.; Dietz, D.W.; Lavery, I.C.; Fazio, V.W.; Kalady, M.F. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann. Surg. Oncol., 2011, 18(6), 1590-1598.
[http://dx.doi.org/10.1245/s10434-010-1506-1] [PMID: 21207164]
[11]
Martin, S.T.; Heneghan, H.M.; Winter, D.C. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br. J. Surg., 2012, 99(7), 918-928.
[http://dx.doi.org/10.1002/bjs.8702] [PMID: 22362002]
[12]
Park, I.J.; You, Y.N.; Agarwal, A.; Skibber, J.M.; Rodriguez-Bigas, M.A.; Eng, C.; Feig, B.W.; Das, P.; Krishnan, S.; Crane, C.H.; Hu, C.Y.; Chang, G.J. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J. Clin. Oncol., 2012, 30(15), 1770-1776.
[http://dx.doi.org/10.1200/JCO.2011.39.7901] [PMID: 22493423]
[13]
Zorcolo, L.; Rosman, A.S.; Restivo, A.; Pisano, M.; Nigri, G.R.; Fancellu, A.; Melis, M. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann. Surg. Oncol., 2012, 19(9), 2822-2832.
[http://dx.doi.org/10.1245/s10434-011-2209-y] [PMID: 22434243]
[14]
AlGizawy, S.M.; Essa, H.H.; Ahmed, B.M. Chemotherapy alone for patients with stage ii/iii rectal cancer undergoing radical Surgery. Oncologist, 2015, 20(7), 752-757.
[http://dx.doi.org/10.1634/theoncologist.2015-0038] [PMID: 26040621]
[15]
McCoy, M.J. Neoadjuvant chemoradiotherapy for rectal cancer: how important is tumour regression? ANZ J. Surg., 2017, 87(12), E233-E239.
[http://dx.doi.org/10.1111/ans.13394] [PMID: 26631340]
[16]
Andrade, V.A.; Coy, C.S.; Leal, R.F.; Fagundes, J.J.; Martinez, C.A. Ayrizono, Mde.L. Neoadjuvant therapy and surgery for rectal cancer. Comparative study between partial and complete pathological response. Arq. Gastroenterol., 2016, 53(3), 163-168.
[http://dx.doi.org/10.1590/S0004-28032016000300008] [PMID: 27438421]
[17]
Maas, M.; Nelemans, P.J.; Valentini, V.; Das, P.; Rödel, C.; Kuo, L.J.; Calvo, F.A.; García-Aguilar, J.; Glynne-Jones, R.; Haustermans, K.; Mohiuddin, M.; Pucciarelli, S.; Small, W., Jr; Suárez, J.; Theodoropoulos, G.; Biondo, S.; Beets-Tan, R.G.; Beets, G.L. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol., 2010, 11(9), 835-844.
[http://dx.doi.org/10.1016/S1470-2045(10)70172-8] [PMID: 20692872]
[18]
Wang, X.J.; Zheng, Z.R.; Chi, P.; Lin, H.M.; Lu, X.R.; Huang, Y. Effect of interval between neoadjuvant chemoradiotherapy and surgery on oncological outcome for rectal cancer: a systematic review and meta-analysis. Gastroenterol. Res. Pract., 2016. 20166756859
[http://dx.doi.org/10.1155/2016/6756859] [PMID: 27190505]
[19]
Fan, W.H.; Xiao, J.; An, X.; Jiang, W.; Li, L.R.; Gao, Y.H.; Chen, G.; Kong, L.H.; Lin, J.Z.; Wang, J.P.; Pan, Z.Z.; Ding, P.R. Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer. J. Cancer Res. Clin. Oncol., 2017, 143(8), 1461-1467.
[http://dx.doi.org/10.1007/s00432-017-2383-9] [PMID: 28386648]
[20]
Liu, Z.; Zhang, X.Y.; Shi, Y.J.; Wang, L.; Zhu, H.T.; Tang, Z.; Wang, S.; Li, X.T.; Tian, J.; Sun, Y.S. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin. Cancer Res., 2017, 23(23), 7253-7262.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-1038] [PMID: 28939744]
[21]
Sun, Y.; Chi, P.; Lin, H.; Lu, X.; Huang, Y.; Xu, Z.; Huang, S.; Wang, X. A nomogram predicting pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: implications for organ preservation strategies. Oncotarget, 2017, 8(40), 67732-67743.
[http://dx.doi.org/10.18632/oncotarget.18821] [PMID: 28978067]
[22]
Perez, K.; Safran, H.; Sikov, W.; Vrees, M.; Klipfel, A.; Shah, N.; Schechter, S.; Oldenburg, N.; Pricolo, V.; Rosati, K.; Dipetrillo, T. Complete neoadjuvant treatment for rectal cancer: the brown university oncology group CONTRE study. Am. J. Clin. Oncol., 2017, 40(3), 283-287.
[http://dx.doi.org/10.1097/COC.0000000000000149] [PMID: 25374145]
[23]
Clarke, T.L.; White, D.A.; Osborne, M.E.; Shaw, A.M.; Smart, N.J.; Daniels, I.R. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers. Ann. R. Coll. Surg. Engl., 2017, 99(5), 373-377.
[http://dx.doi.org/10.1308/rcsann.2017.0030] [PMID: 28462648]
[24]
Ludmir, E.B.; Palta, M.; Willett, C.G.; Czito, B.G. Total neoadjuvant therapy for rectal cancer: An emerging option. Cancer, 2017, 123(9), 1497-1506.
[http://dx.doi.org/10.1002/cncr.30600] [PMID: 28295220]
[25]
Ryan, J.E.; Warrier, S.K.; Lynch, A.C.; Heriot, A.G. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis., 2015, 17(10), 849-861.
[http://dx.doi.org/10.1111/codi.13081] [PMID: 26260213]
[26]
Rödel, C.; Martus, P.; Papadoupolos, T.; Füzesi, L.; Klimpfinger, M.; Fietkau, R.; Liersch, T.; Hohenberger, W.; Raab, R.; Sauer, R.; Wittekind, C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol., 2005, 23(34), 8688-8696.
[http://dx.doi.org/10.1200/JCO.2005.02.1329] [PMID: 16246976]
[27]
Maguire, A.; Sheahan, K. Controversies in the pathological assessment of colorectal cancer. World J. Gastroenterol., 2014, 20(29), 9850-9861.
[http://dx.doi.org/10.3748/wjg.v20.i29.9850] [PMID: 25110416]
[28]
Mandard, A.M.; Dalibard, F.; Mandard, J.C.; Marnay, J.; Henry-Amar, M.; Petiot, J.F.; Roussel, A.; Jacob, J.H.; Segol, P.; Samama, G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer, 1994, 73(11), 2680-2686.
[http://dx.doi.org/10.1002/1097-0142(19940601)73:11<2680:AID-CNCR2820731105>3.0.CO;2-C] [PMID: 8194005]
[29]
Dworak, O.; Keilholz, L.; Hoffmann, A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis., 1997, 12(1), 19-23.
[http://dx.doi.org/10.1007/s003840050072] [PMID: 9112145]
[30]
Wheeler, J.M.; Warren, B.F.; Mortensen, N.J.; Ekanyaka, N.; Kulacoglu, H.; Jones, A.C.; George, B.D.; Kettlewell, M.G. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis. Colon Rectum, 2002, 45(8), 1051-1056.
[http://dx.doi.org/10.1007/s10350-004-6359-x] [PMID: 12195189]
[31]
Ryan, R.; Gibbons, D.; Hyland, J.M.; Treanor, D.; White, A.; Mulcahy, H.E.; O’Donoghue, D.P.; Moriarty, M.; Fennelly, D.; Sheahan, K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology, 2005, 47(2), 141-146.
[http://dx.doi.org/10.1111/j.1365-2559.2005.02176.x] [PMID: 16045774]
[32]
García-Aguilar, J.; Hernandez de Anda, E.; Sirivongs, P.; Lee, S.H.; Madoff, R.D.; Rothenberger, D.A. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis. Colon Rectum, 2003, 46(3), 298-304.
[http://dx.doi.org/10.1007/s10350-004-6545-x] [PMID: 12626903]
[33]
Capirci, C.; Valentini, V.; Cionini, L.; De Paoli, A.; Rodel, C.; Glynne-Jones, R.; Coco, C.; Romano, M.; Mantello, G.; Palazzi, S.; Mattia, F.O.; Friso, M.L.; Genovesi, D.; Vidali, C.; Gambacorta, M.A.; Buffoli, A.; Lupattelli, M.; Favretto, M.S.; La Torre, G. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int. J. Radiat. Oncol. Biol. Phys., 2008, 72(1), 99-107.
[http://dx.doi.org/10.1016/j.ijrobp.2007.12.019] [PMID: 18407433]
[34]
Bujko, K.; Kolodziejczyk, M.; Nasierowska-Guttmejer, A.; Michalski, W.; Kepka, L.; Chmielik, E.; Wojnar, A.; Chwalinski, M. Polish Colorectal Cancer Group. Tumour regression grading in patients with residual rectal cancer after preoperative chemoradiation. Radiother. Oncol., 2010, 95(3), 298-302.
[http://dx.doi.org/10.1016/j.radonc.2010.04.005] [PMID: 20430458]
[35]
Eich, H.T.; Stepien, A.; Zimmermann, C.; Hellmich, M.; Metzger, R.; Hölscher, A.; Müller, R.P. Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression. Strahlenther. Onkol., 2011, 187(4), 225-230.
[http://dx.doi.org/10.1007/s00066-011-2113-1] [PMID: 21424305]
[36]
Huebner, M.; Wolff, B.G.; Smyrk, T.C.; Aakre, J.; Larson, D.W. Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy. World J. Surg., 2012, 36(3), 675-683.
[http://dx.doi.org/10.1007/s00268-011-1409-8] [PMID: 22270980]
[37]
Abdul-Jalil, K.I.; Sheehan, K.M.; Kehoe, J.; Cummins, R.; O’Grady, A.; McNamara, D.A.; Deasy, J.; Breathnach, O.; Grogan, L.; O’Neill, B.D.; Faul, C.; Parker, I.; Kay, E.W.; Hennessy, B.T.; Gillen, P. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer. Colorectal Dis., 2014, 16(1), O16-O25.
[http://dx.doi.org/10.1111/codi.12439] [PMID: 24119076]
[38]
Tomono, A.; Yamashita, K.; Kanemitsu, K.; Sumi, Y.; Yamamoto, M.; Kanaji, S.; Imanishi, T.; Nakamura, T.; Suzuki, S.; Tanaka, K.; Kakeji, Y. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Int. J. Clin. Oncol., 2016, 21(2), 344-349.
[http://dx.doi.org/10.1007/s10147-015-0900-x] [PMID: 26338272]
[39]
Mancini, R.; Pattaro, G.; Diodoro, M.G.; Sperduti, I.; Garufi, C.; Perri, P.; Grazi, V.J.L.; Cosimelli, M. Tumor Regression Grade after neoadjuvant chemoradiation and surgery for low rectal cancer evaluated by multiple correspondence analysis: ten years as minimum follow-up. Clin. Colorectal Cancer, 2017, 17(1), e13-e19.
[http://dx.doi.org/10.1016/j.clcc.2017.06.004] [PMID: 28865674]
[40]
Biomarkers Definitions Working Group. Atkinson, Jr A.J.; Colburn, W.A.; DeGruttola, V.G.; DeMets, D.L.; Downing, G.J.; Hoth, D.F.; Oates, J.A.; Peck, C.C.; Schooley, R.T.; Spilker, B.A. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69(3), 89-95.
[http://dx.doi.org/10.1067/mcp.2001.113989] [PMID: 11240971]
[41]
Ide, S.; Toiyama, Y.; Okugawa, Y.; Oki, S.; Yasuda, H.; Fujikawa, H.; Yoshiyama, S.; Hiro, J.; Kobayashi, M.; Ohi, M.; Araki, T.; Kusunoki, M. Clinical significance of c-reactive protein-to-albumin ratio with rectal cancer patient undergoing chemoradiotherapy followed by surgery. Anticancer Res., 2017, 37(10), 5797-5804.
[http://dx.doi.org/234526789/:;<=/:.>?425355] [PMID: 28982904]
[42]
Suzuki, T.; Shimada, H.; Ushigome, M.; Koike, J.; Funahashi, K.; Nemoto, T.; Kaneko, H. Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin. J. Gastroenterol., 2016, 9(2), 55-58.
[http://dx.doi.org/10.1007/s12328-016-0633-z] [PMID: 26919859]
[43]
Ballman, K.V. Biomarker: Predictive or Prognostic? J. Clin. Oncol., 2015, 33(33), 3968-3971.
[http://dx.doi.org/10.1200/JCO.2015.63.3651] [PMID: 26392104]
[44]
Minden, M. Is it time to redefine prognostic and predictive in oncology? J. Clin. Oncol., 2016, 34(14), 1702-1703.
[http://dx.doi.org/10.1200/JCO.2015.66.3815] [PMID: 26976412]
[45]
Tan, C.; Du, X. KRAS mutation testing in metastatic colorectal cancer. World J. Gastroenterol., 2012, 18(37), 5171-5180.
[http://dx.doi.org/10.3748/wjg.v18.i37.5171] [PMID: 23066310]
[46]
Walker, A.S.; Zwintscher, N.P.; Johnson, E.K.; Maykel, J.A.; Stojadinovic, A.; Nissan, A.; Avital, I.; Brücher, B.L.; Steele, S.R. Future directions for monitoring treatment response in colorectal cancer. J. Cancer, 2014, 5(1), 44-57.
[http://dx.doi.org/10.7150/jca.7809] [PMID: 24396497]
[47]
Armstrong, D.; Raissouni, S.; Price Hiller, J.; Mercer, J.; Powell, E.; MacLean, A.; Jiang, M.; Doll, C.; Goodwin, R.; Batuyong, E.; Zhou, K.; Monzon, J.G.; Tang, P.A.; Heng, D.Y.; Cheung, W.Y.; Vickers, M.M. Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: a multicenter study. Clin. Colorectal Cancer, 2015, 14(4), 291-295.
[http://dx.doi.org/10.1016/j.clcc.2015.06.001] [PMID: 26433487]
[48]
Kim, N.K.; Hur, H. New Perspectives on predictive biomarkers of tumor response and their clinical application in preoperative chemoradiation therapy for rectal cancer. new perspectives on predictive biomarkers of tumor response and their clinical application in preoperative chemoradiation therapy for rectal cancer. Yonsei Med. J., 2015, 56(6), 1461-1477.
[http://dx.doi.org/10.3349/ymj.2015.56.6.1461] [PMID: 26446626]
[49]
Yoo, B.C.; Yeo, S.G. Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review. EPMA J., 2017, 8(1), 61-67.
[http://dx.doi.org/10.1007/s13167-017-0082-x] [PMID: 28620444]
[50]
Nakao, T.; Iwata, T.; Hotchi, M.; Yoshikawa, K.; Higashijima, J.; Nishi, M.; Takasu, C.; Eto, S.; Teraoku, H.; Shimada, M. Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer. Oncol. Rep., 2015, 34(4), 1961-1967.
[http://dx.doi.org/10.3892/or.2015.4196] [PMID: 26260776]
[51]
Agostini, M.; Crotti, S.; Bedin, C.; Cecchin, E.; Maretto, I.; D’Angelo, E.; Pucciarelli, S.; Nitti, D. Predictive response biomarkers in rectal cancer neoadjuvant treatment. Front. Biosci. (Schol. Ed.), 2014, 6, 110-119.
[http://dx.doi.org/10.2741/S418] [PMID: 24389265]
[52]
Dayde, D.; Tanaka, I.; Jain, R.; Tai, M.C.; Taguchi, A. Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. Int. J. Mol. Sci., 2017, 18(3) E573
[http://dx.doi.org/10.3390/ijms18030573] [PMID: 28272347]
[53]
Molinari, C.; Matteucci, F.; Caroli, P.; Passardi, A. Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Clin. Colorectal Cancer, 2015, 14(4), 227-238.
[http://dx.doi.org/10.1016/j.clcc.2015.05.014] [PMID: 26170142]
[54]
Conde-Muíño, R.; Cuadros, M.; Zambudio, N.; Segura-Jiménez, I.; Cano, C.; Palma, P. Predictive biomarkers to chemoradiation in locally advanced rectal cancer. BioMed Res. Int., 2015., 2015921435
[http://dx.doi.org/10.1155/2015/921435] [PMID: 26504848]
[55]
Lu, S.H.; Tsai, W.S.; Chang, Y.H.; Chou, T.Y.; Pang, S.T.; Lin, P.H.; Tsai, C.M.; Chang, Y.C. Identifying cancer origin using circulating tumor cells. Cancer Biol. Ther., 2016, 17(4), 430-438.
[http://dx.doi.org/10.1080/15384047.2016.1141839] [PMID: 26828696]
[56]
Pantel, K.; Speicher, M.R. The biology of circulating tumor cells. Oncogene, 2016, 35(10), 1216-1224.
[http://dx.doi.org/10.1038/onc.2015.192] [PMID: 26050619]
[57]
Chen, L.; Bode, A.M.; Dong, Z. Circulating tumor cells: moving biological insights into detection. Theranostics, 2017, 7(10), 2606-2619.
[http://dx.doi.org/10.7150/thno.18588] [PMID: 28819450]
[58]
Alix-Panabières, C.; Pantel, K. Challenges in circulating tumour cell research. Nat. Rev. Cancer, 2014, 14(9), 623-631.
[http://dx.doi.org/10.1038/nrc3820] [PMID: 25154812]
[59]
Millner, L.M.; Linder, M.W.; Valdes, R. Jr Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann. Clin. Lab. Sci., 2013, 43(3), 295-304.
[PMID: 23884225]
[60]
Nesteruk, D.; Rutkowski, A.; Fabisiewicz, S.; Pawlak, J.; Siedlecki, J.A.; Fabisiewicz, A. Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data. BioMed Res. Int., 2014. ,2014712827
[61]
Hinz, S.; Röder, C.; Tepel, J.; Hendricks, A.; Schafmayer, C.; Becker, T.; Kalthoff, H. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. BMC Cancer, 2015, 15, 953.
[http://dx.doi.org/10.1186/s12885-015-1989-z] [PMID: 26674974]
[62]
Magni, E.; Botteri, E.; Ravenda, P.S.; Cassatella, M.C.; Bertani, E.; Chiappa, A.; Luca, F.; Zorzino, L.; Bianchi, P.P.; Adamoli, L.; Sandri, M.T.; Zampino, M.G. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int. J. Colorectal Dis., 2014, 29(9), 1053-1059.
[http://dx.doi.org/10.1007/s00384-014-1958-z] [PMID: 25008360]
[63]
Sun, W.; Huang, T.; Li, G.; Shen, W.; Zhu, J.; Jin, Q.; Zhao, J.; Jia, C.; Zhang, Z. The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer. Future Oncol., 2013, 9(10), 1489-1500.
[http://dx.doi.org/10.2217/fon.13.91] [PMID: 24106900]
[64]
Sun, W.; Li, G.; Wan, J.; Zhu, J.; Shen, W.; Zhang, Z. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget, 2016, 7(43), 69507-69517.
[http://dx.doi.org/10.18632/oncotarget.10875] [PMID: 27486758]
[65]
Sun, W.; Jia, C.; Huang, T.; Sheng, W.; Li, G.; Zhang, H.; Jing, F.; Jin, Q.; Zhao, J.; Li, G.; Zhang, Z. High-performance size-based microdevice for the detection of circulating tumor cells from peripheral blood in rectal cancer patients. PLoS One, 2013, 8(9) e75865
[http://dx.doi.org/10.1371/journal.pone.0075865] [PMID: 24066187]
[66]
Mandel, P.; Metais, P. Les acides nucléiques du plasma sanguin chez l’homme. C. R. Seances Soc. Biol. Fil., 1948, 142(3-4), 241-243.
[PMID: 18875018]
[67]
Stroun, M.; Lyautey, J.; Lederrey, C.; Olson-Sand, A.; Anker, P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta, 2001, 313(1-2), 139-142.
[http://dx.doi.org/10.1016/S0009-8981(01)00665-9] [PMID: 11694251]
[68]
Ziegler, A.; Zangemeister-Wittke, U.; Stahel, R.A.; Circulating, D.N.A. Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev., 2002, 28(5), 255-271.
[http://dx.doi.org/10.1016/S0305-7372(02)00077-4] [PMID: 12435372]
[69]
Diaz, L.A., Jr; Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol., 2014, 32(6), 579-586.
[http://dx.doi.org/10.1200/JCO.2012.45.2011] [PMID: 24449238]
[70]
Warton, K.; Samimi, G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front. Mol. Biosci., 2015, 2, 13.
[http://dx.doi.org/10.3389/fmolb.2015.00013] [PMID: 25988180]
[71]
Mokarram, P.; Rismanchi, M.; Alizadeh Naeeni, M.; Mirab Samiee, S.; Paryan, M.; Alipour, A.; Honardar, Z.; Kavousipour, S.; Naghibalhossaini, F.; Mostafavi-Pour, Z.; Monabati, A.; Hosseni, S.V.; Shamsdin, S.A. Microsatellite instability typing in serum and tissue of patients with colorectal cancer: comparing real time PCR with hybridization probe and high-performance liquid chromatography. Mol. Biol. Rep., 2014, 41(5), 2835-2844.
[http://dx.doi.org/10.1007/s11033-014-3138-1] [PMID: 24452720]
[72]
Bedin, C.; Enzo, M.V.; Del Bianco, P.; Pucciarelli, S.; Nitti, D.; Agostini, M. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int. J. Cancer, 2017, 140(8), 1888-1898.
[http://dx.doi.org/10.1002/ijc.30565] [PMID: 27943272]
[73]
Sikora, K.; Bedin, C.; Vicentini, C.; Malpeli, G.; D’Angelo, E.; Sperandio, N.; Lawlor, R.T.; Bassi, C.; Tortora, G.; Nitti, D.; Agostini, M.; Fassan, M.; Scarpa, A. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int. J. Biol. Markers, 2015, 30(1), e136-e141.
[http://dx.doi.org/10.5301/jbm.5000088] [PMID: 24832178]
[74]
Agostini, M.; Enzo, M.V.; Bedin, C.; Belardinelli, V.; Goldin, E.; Del Bianco, P.; Maschietto, E.; D’Angelo, E.; Izzi, L.; Saccani, A.; Zavagno, G.; Nitti, D. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark., 2012, 11(2-3), 89-98.
[http://dx.doi.org/10.3233/CBM-2012-0263] [PMID: 23011155]
[75]
Sun, W.; Sun, Y.; Zhu, M.; Wang, Z.; Zhang, H.; Xin, Y.; Jiang, G.; Guo, X.; Zhang, Z.; Liu, Y. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol. Rep., 2014, 31(3), 1466-1472.
[http://dx.doi.org/10.3892/or.2013.2949] [PMID: 24378613]
[76]
Agostini, M.; Pucciarelli, S.; Enzo, M.V.; Del Bianco, P.; Briarava, M.; Bedin, C.; Maretto, I.; Friso, M.L.; Lonardi, S.; Mescoli, C.; Toppan, P.; Urso, E.; Nitti, D. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann. Surg. Oncol., 2011, 18(9), 2461-2468.
[http://dx.doi.org/10.1245/s10434-011-1638-y] [PMID: 21416156]
[77]
Misale, S.; Yaeger, R.; Hobor, S.; Scala, E.; Janakiraman, M.; Liska, D.; Valtorta, E.; Schiavo, R.; Buscarino, M.; Siravegna, G.; Bencardino, K.; Cercek, A.; Chen, C.T.; Veronese, S.; Zanon, C.; Sartore-Bianchi, A.; Gambacorta, M.; Gallicchio, M.; Vakiani, E.; Boscaro, V.; Medico, E.; Weiser, M.; Siena, S.; Di Nicolantonio, F.; Solit, D.; Bardelli, A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486(7404), 532-536.
[http://dx.doi.org/10.1038/nature11156] [PMID: 22722830]
[78]
Bengala, C.; Bettelli, S.; Bertolini, F.; Sartori, G.; Fontana, A.; Malavasi, N.; Depenni, R.; Zironi, S.; Del Giovane, C.; Luppi, G.; Conte, P.F. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br. J. Cancer, 2010, 103(7), 1019-1024.
[http://dx.doi.org/10.1038/sj.bjc.6605853] [PMID: 20842128]
[79]
Grimminger, P.P.; Danenberg, P.; Dellas, K.; Arnold, D.; Rödel, C.; Machiels, J.P.; Haustermans, K.; Debucquoy, A.; Velenik, V.; Sempoux, C.; Bracko, M.; Hölscher, A.H.; Semrau, R.; Yang, D.; Danenberg, K.; Lenz, H.J.; Vallböhmer, D. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin. Cancer Res., 2011, 17(10), 3469-3477.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-2273] [PMID: 21558395]
[80]
Erben, P.; Ströbel, P.; Horisberger, K.; Popa, J.; Bohn, B.; Hanfstein, B.; Kähler, G.; Kienle, P.; Post, S.; Wenz, F.; Hochhaus, A.; Hofheinz, R.D. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab based chemoradiotherapy in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2011, 81(4), 1032-1038.
[http://dx.doi.org/10.1016/j.ijrobp.2010.06.043] [PMID: 20947270]
[81]
Sun, P.L.; Li, B.; Ye, Q.F. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. Int. J. Colorectal Dis., 2012, 27(10), 1325-1332.
[http://dx.doi.org/10.1007/s00384-012-1446-2] [PMID: 22430888]
[82]
Derbel, O.; Wang, Q.; Desseigne, F.; Rivoire, M.; Meeus, P.; Peyrat, P.; Stella, M.; Martel-Lafay, I.; Lemaistre, A.I.; de La Fouchardière, C. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. BMC Cancer, 2013, 13, 200.
[http://dx.doi.org/10.1186/1471-2407-13-200] [PMID: 23617638]
[83]
Clancy, C.; Burke, J.P.; Coffey, J.C. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Surg. Oncol., 2013, 22(2), 105-111.
[http://dx.doi.org/10.1016/j.suronc.2013.02.001] [PMID: 23473635]
[84]
Duldulao, M.P.; Lee, W.; Nelson, R.A.; Li, W.; Chen, Z.; Kim, J.; Garcia-Aguilar, J. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann. Surg. Oncol., 2013, 20(7), 2166-2171.
[http://dx.doi.org/10.1245/s10434-013-2910-0] [PMID: 23456389]
[85]
Russo, A.L.; Ryan, D.P.; Borger, D.R.; Wo, J.Y.; Szymonifka, J.; Liang, W.Y.; Kwak, E.L.; Blaszkowsky, L.S.; Clark, J.W.; Allen, J.N.; Zhu, A.X.; Berger, D.L.; Cusack, J.C.; Mamon, H.J.; Haigis, K.M.; Hong, T.S. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J. Gastrointest. Cancer, 2014, 45(1), 34-39.
[http://dx.doi.org/10.1007/s12029-013-9546-y] [PMID: 24006244]
[86]
Sclafani, F.; Gonzalez, D.; Cunningham, D.; Hulkki Wilson, S.; Peckitt, C.; Giralt, J.; Glimelius, B.; Roselló Keränen, S.; Wotherspoon, A.; Brown, G.; Tait, D.; Oates, J.; Chau, I. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. Eur. J. Cancer, 2014, 50(8), 1430-1436.
[http://dx.doi.org/10.1016/j.ejca.2014.02.002] [PMID: 24582914]
[87]
Martellucci, J.; Alemanno, G.; Castiglione, F.; Bergamini, C.; Valeri, A. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. Updates Surg., 2015, 67(1), 47-53.
[http://dx.doi.org/10.1007/s13304-015-0281-8] [PMID: 25702261]
[88]
Salnikova, L.E.; Kolobkov, D.S. Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. Pharmacogenomics J., 2016, 16(3), 249-265.
[http://dx.doi.org/10.1038/tpj.2015.46] [PMID: 26122021]
[89]
Chow, O.S.; Kuk, D.; Keskin, M.; Smith, J.J.; Camacho, N.; Pelossof, R.; Chen, C.T.; Chen, Z.; Avila, K.; Weiser, M.R.; Berger, M.F.; Patil, S.; Bergsland, E.; Garcia-Aguilar, J. KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant Therapy. Ann. Surg. Oncol., 2016, 23(8), 2548-2555.
[http://dx.doi.org/10.1245/s10434-016-5205-4] [PMID: 27020587]
[90]
Tóth, K.; Wasserkort, R.; Sipos, F.; Kalmár, A.; Wichmann, B.; Leiszter, K.; Valcz, G.; Juhász, M.; Miheller, P.; Patai, Á.V.; Tulassay, Z.; Molnár, B. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One, 2014, 9(12) e115415
[http://dx.doi.org/10.1371/journal.pone.0115415] [PMID: 25526039]
[91]
Wu, D.; Zhou, G.; Jin, P.; Zhu, J.; Li, S.; Wu, Q.; Wang, G.; Sheng, J.; Wang, J.; Song, L.; Han, X.; Qian, J. Detection of colorectal cancer using a simplified sept9 gene methylation assay is a reliable method for opportunistic screening. J. Mol. Diagn., 2016, 18(4), 535-545.
[http://dx.doi.org/10.1016/j.jmoldx.2016.02.005] [PMID: 27133379]
[92]
Mori, T.; O’Day, S.J.; Umetani, N.; Martinez, S.R.; Kitago, M.; Koyanagi, K.; Kuo, C.; Takeshima, T.L.; Milford, R.; Wang, H.J.; Vu, V.D.; Nguyen, S.L.; Hoon, D.S. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol., 2005, 23(36), 9351-9358.
[http://dx.doi.org/10.1200/JCO.2005.02.9876] [PMID: 16361635]
[93]
Avraham, A.; Uhlmann, R.; Shperber, A.; Birnbaum, M.; Sandbank, J.; Sella, A.; Sukumar, S.; Evron, E. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int. J. Cancer, 2012, 131(7), E1166-E1172.
[http://dx.doi.org/10.1002/ijc.27526] [PMID: 22407753]
[94]
Shalaby, S.M. Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients. Gene, 2017.
[PMID: 29080834]
[95]
Macfarlane, L.A.; Murphy, P.R.; Micro, R.N.A. MicroRNA: biogenesis, function and role in cancer. Curr. Genomics, 2010, 11(7), 537-561.
[http://dx.doi.org/10.2174/138920210793175895] [PMID: 21532838]
[96]
Sohel, M.H. Extracellular/circulating MicroRNAs: release mechanisms, functions and challenges. Achievements in the Life Sciences, 2016, 10(2), 175-186.
[http://dx.doi.org/10.1016/j.als.2016.11.007]
[97]
D’Angelo, E.; Vicentini, C.; Agostini, M.; Kiss, A.; Baffa, R.; Scarpa, A.; Fassan, M. MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis. Curr. Drug Targets, 2015, 16(4), 383-392.
[http://dx.doi.org/10.2174/1389450116666141210091454] [PMID: 25495924]
[98]
D’Angelo, E. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. J. Clin. Pathol., 2017.
[http://dx.doi.org/10.1016/j.gene.2017.10.056] [PMID: 28870889]
[99]
Agostini, M.; Janssen, K.P.; Kim, I.J.; D’Angelo, E.; Pizzini, S.; Zangrando, A.; Zanon, C.; Pastrello, C.; Maretto, I.; Digito, M.; Bedin, C.; Jurisica, I.; Rizzolio, F.; Giordano, A.; Bortoluzzi, S.; Nitti, D.; Pucciarelli, S. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget, 2015, 6(32), 32561-32574.
[http://dx.doi.org/10.18632/oncotarget.4935] [PMID: 26359356]
[100]
Agostini, M.; Zangrando, A.; Pastrello, C.; D’Angelo, E.; Romano, G.; Giovannoni, R.; Giordan, M.; Maretto, I.; Bedin, C.; Zanon, C.; Digito, M.; Esposito, G.; Mescoli, C.; Lavitrano, M.; Rizzolio, F.; Jurisica, I.; Giordano, A.; Pucciarelli, S.; Nitti, D. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol. Ther., 2015, 16(8), 1160-1171.
[http://dx.doi.org/10.1080/15384047.2015.1046652] [PMID: 26023803]
[101]
Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008, 105(30), 10513-10518.
[http://dx.doi.org/10.1073/pnas.0804549105] [PMID: 18663219]
[102]
Azizian, A.; Kramer, F.; Jo, P.; Wolff, H.A.; Beißbarth, T.; Skarupke, R.; Bernhardt, M.; Grade, M.; Ghadimi, B.M.; Gaedcke, J. Preoperative prediction of lymph node status by circulating mir-18b and mir-20a during chemoradiotherapy in patients with rectal cancer. World J. Surg., 2015, 39(9), 2329-2335.
[http://dx.doi.org/10.1007/s00268-015-3083-8] [PMID: 25990502]
[103]
D’Angelo, E.; Fassan, M.; Maretto, I.; Pucciarelli, S.; Zanon, C.; Digito, M.; Rugge, M.; Nitti, D.; Agostini, M. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. Oncotarget, 2016, 7(19), 28647-28657.
[http://dx.doi.org/10.18632/oncotarget.8725] [PMID: 27081702]
[104]
Yu, J.; Li, N.; Wang, X.; Ren, H.; Wang, W.; Wang, S.; Song, Y.; Liu, Y.; Li, Y.; Zhou, X.; Luo, A.; Liu, Z.; Jin, J. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget, 2016, 7(39), 64233-64243.
[http://dx.doi.org/10.18632/oncotarget.11649] [PMID: 27572313]
[105]
Parker, C.E.; Borchers, C.H. Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays. Mol. Oncol., 2014, 8(4), 840-858.
[http://dx.doi.org/10.1016/j.molonc.2014.03.006] [PMID: 24713096]
[106]
Smith, F.M.; Gallagher, W.M.; Fox, E.; Stephens, R.B.; Rexhepaj, E.; Petricoin, E.F., III; Liotta, L.; Kennedy, M.J.; Reynolds, J.V. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann. Surg., 2007, 245(2), 259-266.
[http://dx.doi.org/10.1097/01.sla.0000245577.68151.bd] [PMID: 17245180]
[107]
Repetto, O.; De Re, V.; De Paoli, A.; Belluco, C.; Alessandrini, L.; Canzonieri, V.; Cannizzaro, R. Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy. Oncotarget, 2017, 8(17), 28328-28341.
[http://dx.doi.org/10.18632/oncotarget.16053] [PMID: 28423701]
[108]
Lee, J.H.; Hyun, J.H.; Kim, D.Y.; Yoo, B.C.; Park, J.W.; Kim, S.Y.; Chang, H.J.; Kim, B.C.; Kim, T.H.; Oh, J.H.; Sohn, D.K. The role of fibrinogen as a predictor in preoperative chemoradiation for rectal cancer. Ann. Surg. Oncol., 2015, 22(1), 209-215.
[http://dx.doi.org/10.1245/s10434-014-3962-5] [PMID: 25384698]
[109]
Han, Y.D.; Kim, W.R.; Park, S.W.; Cho, M.S.; Hur, H.; Min, B.S.; Baik, S.H.; Lee, K.Y.; Kim, N.K. Predictors of pathologic complete response in rectal cancer patients undergoing total mesorectal excision after preoperative chemoradiation. Medicine (Baltimore), 2015, 94(45)e1971
[http://dx.doi.org/10.1097/MD.0000000000001971] [PMID: 26559272]
[110]
Buijsen, J.; van Stiphout, R.G.; Menheere, P.P.; Lammering, G.; Lambin, P. Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer. Radiother. Oncol., 2014, 111(2), 237-242.
[http://dx.doi.org/10.1016/j.radonc.2014.03.006] [PMID: 24746569]
[111]
Giessen, C.; Nagel, D.; Glas, M.; Spelsberg, F.; Lau-Werner, U.; Modest, D.P.; Michl, M.; Heinemann, V.; Stieber, P.; Schulz, C. Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer. Tumour Biol., 2014, 35(10), 10237-10248.
[http://dx.doi.org/10.1007/s13277-014-2338-6] [PMID: 25027407]
[112]
FDA-NIH Biomarker Working Group. Best (biomarkers, endpoints, and other tools). Food and Drug Administration (US), Silver Spring (MD) In: Co-published by National Institutes of Health (US), Bethesda (MD); , 2016.
[113]
Kleiman, A.; Al-Khamis, A.; Farsi, A.; Kezouh, A.; Vuong, T.; Gordon, P.H.; Vasilevsky, C.A.; Morin, N.; Faria, J.; Ghitulescu, G.; Boutros, M. Normalization of CEA levels post-neoadjuvant therapy is a strong predictor of pathologic complete response in rectal cancer. J. Gastrointest. Surg., 2015, 19(6), 1106-1112.
[http://dx.doi.org/10.1007/s11605-015-2814-3] [PMID: 25859755]
[114]
Chung, M.J.; Nam, T.K.; Jeong, J.U.; Kim, S.H.; Kim, K.; Jang, H.S.; Jeong, B.K.; Lee, J.H. Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study. Int. J. Colorectal Dis., 2016, 31(9), 1595-1601.
[http://dx.doi.org/10.1007/s00384-016-2629-z] [PMID: 27464635]
[115]
Benej, M.; Pastorekova, S.; Pastorek, J. Carbonic anhydrase IX: regulation and role in cancer. Subcell. Biochem., 2014, 75, 199-219.
[http://dx.doi.org/10.1007/978-94-007-7359-2_11] [PMID: 24146381]
[116]
Hektoen, H.H.; Flatmark, K.; Andersson, Y.; Dueland, S.; Redalen, K.R.; Ree, A.H. Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer. BMC Cancer, 2015, 15, 543.
[http://dx.doi.org/10.1186/s12885-015-1557-6] [PMID: 26205955]
[117]
Crotti, S.; Piccoli, M.; Rizzolio, F.; Giordano, A.; Nitti, D.; Agostini, M. Extracellular matrix and colorectal cancer: how surrounding microenvironment affects cancer cell behavior? J. Cell. Physiol., 2017, 232(5), 967-975.
[http://dx.doi.org/10.1002/jcp.25658] [PMID: 27775168]
[118]
Sørensen, N.M.; Byström, P.; Christensen, I.J.; Berglund, A.; Nielsen, H.J.; Brünner, N.; Glimelius, B. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin. Cancer Res., 2007, 13(14), 4117-4122.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-0186] [PMID: 17634538]
[119]
Aldulaymi, B.; Christensen, I.J.; Sölétormos, G.; Jess, P.; Nielsen, S.E.; Laurberg, S.; Brünner, N.; Nielsen, H.J. Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer. Anticancer Res., 2010, 30(11), 4755-4759.
[PMID: 21115936]
[120]
Yoon, H.I.; Koom, W.S.; Kim, Y.B.; Min, B.S.; Lee, K.Y.; Kim, N.K.; Shin, S.J.; Ahn, J.B.; Keum, K.C. Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. J. Cancer Res. Clin. Oncol., 2014, 140(3), 399-409.
[http://dx.doi.org/10.1007/s00432-013-1578-y] [PMID: 24390211]
[121]
Bedin, C.; Crotti, S.; Ragazzi, E.; Pucciarelli, S.; Agatea, L.; Tasciotti, E.; Ferrari, M.; Traldi, P.; Rizzolio, F.; Giordano, A.; Nitti, D.; Agostini, M. Alterations of the plasma peptidome profiling in colorectal cancer progression. J. Cell. Physiol., 2016, 231(4), 915-925.
[http://dx.doi.org/10.1002/jcp.25196] [PMID: 26379225]
[122]
Agatea, L.; Crotti, S.; Ragazzi, E.; Bedin, C.; Urso, E.; Mammi, I.; Traldi, P.; Pucciarelli, S.; Nitti, D.; Agostini, M. Peptide patterns as discriminating biomarkers in plasma of patients with familial adenomatous polyposis. Clin. Colorectal Cancer, 2016, 15(3), e75-e92.
[http://dx.doi.org/10.1016/j.clcc.2015.12.002] [PMID: 26792031]
[123]
Villanueva, J.; Shaffer, D.R.; Philip, J.; Chaparro, C.A.; Erdjument-Bromage, H.; Olshen, A.B.; Fleisher, M.; Lilja, H.; Brogi, E.; Boyd, J.; Sanchez-Carbayo, M.; Holland, E.C.; Cordon-Cardo, C.; Scher, H.I.; Tempst, P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest., 2006, 116(1), 271-284.
[http://dx.doi.org/10.1172/JCI26022] [PMID: 16395409]
[124]
Caine, G.J.; Stonelake, P.S.; Lip, G.Y.; Kehoe, S.T. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia, 2002, 4(6), 465-473.
[http://dx.doi.org/10.1038/sj.neo.7900263] [PMID: 12407439]
[125]
Lima, L.G.; Monteiro, R.Q. Activation of blood coagulation in cancer: implications for tumour progression. Biosci. Rep., 2013, 33(5) e00064
[http://dx.doi.org/10.1042/BSR20130057] [PMID: 23889169]
[126]
Crotti, S.; Enzo, M.V.; Bedin, C.; Pucciarelli, S.; Maretto, I.; Del Bianco, P.; Traldi, P.; Tasciotti, E.; Ferrari, M.; Rizzolio, F.; Toffoli, G.; Giordano, A.; Nitti, D.; Agostini, M. Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy. J. Cell. Physiol., 2015, 230(8), 1822-1828.
[http://dx.doi.org/10.1002/jcp.24894] [PMID: 25522009]
[127]
Jo, P.; König, A.; Schirmer, M.; Kitz, J.; Conradi, L.C.; Azizian, A.; Bernhardt, M.; Wolff, H.A.; Grade, M.; Ghadimi, M.; Ströbel, P.; Schildhaus, H.U.; Gaedcke, J. Heterogeneity of KRAS mutation status in rectal cancer. PLoS One, 2016, 11(4) e0153278
[http://dx.doi.org/10.1371/journal.pone.0153278] [PMID: 27064574]
[128]
Rödel, C.; Hofheinz, R.; Fokas, E. Rectal cancer: Neoadjuvant chemoradiotherapy. Best Pract. Res. Clin. Gastroenterol., 2016, 30(4), 629-639.
[http://dx.doi.org/10.1016/j.bpg.2016.06.004] [PMID: 27644910]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy